Combined medicine capable of simultaneously amplifying immunogenic cell death and enhancing anti-tumor effect

A technology of cell death and immunogenicity, applied in the field of medicine, can solve the problems of immunogenic cell death, and achieve the effect of enhancing phagocytosis and maturation, improving immunogenicity and amplifying cell death

Active Publication Date: 2021-03-23
SICHUAN UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to solve the problem that currently used chemotherapeutic drugs cannot induce immunogenic cell death

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicine capable of simultaneously amplifying immunogenic cell death and enhancing anti-tumor effect
  • Combined medicine capable of simultaneously amplifying immunogenic cell death and enhancing anti-tumor effect
  • Combined medicine capable of simultaneously amplifying immunogenic cell death and enhancing anti-tumor effect

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 Synthesis of 3-(aminopropyl) methacrylamide (amino) modified HPMA polymer

[0043] Mix 30 ml of freshly steamed methacryloyl chloride with 15 ml of dichloromethane, and slowly drop it into 77 ml of dichloromethane solution containing 21 ml of 1-amino-2-propanol and 32 g of sodium carbonate. Warmed to room temperature, stirred for 1h. Then the reaction solution was placed in a low-temperature cold bath at -50°C for 1 h, and a white precipitate was generated. After filtration, the precipitate was recrystallized with acetone, and the white crystal was HPMA monomer.

[0044] With 2, 2'-azobisisobutyronitrile (AIBN) as the initiator and methanol as the solvent, polymer monomers HPMA, 3-(aminopropyl) methacrylamide salt (APMA) (HPMA:APMA= 80: 20 mol%) to generate HPMA polymer precursors by radical polymerization solution reaction (polymer monomer: initiator: solvent = 12.5:2:85.5 wt%).

[0045] AIBN, HPMA and APMA were weighed into ampoules according to the above...

Embodiment 2

[0046] Example 2 Synthesis of Cytotoxic HPMA Polymer Cisplatin Conjugates

[0047] Disperse 100 mg of cisplatin in 5 ml of deionized water and heat it in a water bath to 50°C, add 3 ml of 30% hydrogen peroxide solution dropwise under stirring and react for 2 hours. Cooled and filtered to obtain light yellow hydroxyl derivatized cisplatin solid c,c,t-[PtCl 2 (OH) 2 (NH 3 ) 2 ].

[0048] Mix 1 ml of dimethyl sulfoxide solution containing 50 mg hydroxyl derivatized cisplatin and dimethyl sulfoxide solution containing 15 mg succinic anhydride, react at 40°C for 24 hours, the reaction solution is precipitated in ether and washed with methanol , the resulting yellow solid was filtered and dried in vacuo to give the carboxyl-derivatized cisplatin solid c,c,t-[PtCl 2 (OH)(NH 3 ) 2 (O 2 CCH 2 CH 2 CO 2 H)].

[0049] Dissolve 20 mg carboxy-derivatized cisplatin, 14.45 mg 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 5.56 mg N-hydroxysuccinimide in 200 μl DM...

Embodiment 3

[0050] Example 3 Flow cytometry detection of the effect of HPMA polymer cisplatin conjugate and digoxin on the cell cycle and apoptosis of B16F10 cells

[0051] Melanoma B16F10 cells were seeded into 12-well plates at 5000 / well, and placed in a cell culture incubator to adhere to the wall for 24 hours. Divided into control group, digoxin group, cisplatin group, cisplatin + digoxin group, HPMA polymer cisplatin conjugate group and HPMA polymer cisplatin conjugate group + digoxin group for the test:

[0052] Control group: add 2 ml RPMI1640 medium (containing 10% FBS);

[0053] Digoxin group: Add 2 ml of RPMI1640 medium containing 62.4 μg / ml digoxin (containing 10% FBS);

[0054] Cisplatin group: Add 2 ml of RPMI1640 medium (containing 10% FBS) containing 100 μg / ml cisplatin;

[0055] Cisplatin + digoxin: Add 2 ml of RPMI1640 medium (containing 10% FBS) containing 100 μg / ml cisplatin and 62.4 μg / ml digoxin;

[0056] HPMA polymer cisplatin conjugate group: Add 2 ml of RPMI1640...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention discloses combined medicine capable of simultaneously amplifying immunogenic cell death and enhancing an anti-tumor effect. The anti-tumor combined medicine comprises a cardiac glycosidecompound used as an active ingredient and a cytotoxic N-(2-hydroxypropyl) methacrylamide HPMA polymer medicine conjugate, wherein the cardiac glycoside compound is at least one of clinical medicine including digoxin, digitonin, deacetylated erioflorin, erioflorin C, G erioflorin, oleandrine and erioflorin K. The cytotoxic HPMA polymer medicine conjugate is an HPMA conjugate carrying at least oneof cis-platinum, carboplatin, nedaplatin, oxaliplatin, lerplatinum and heptplatinum. According to the invention, the cardiac glycoside compound and the N-(2-hydroxypropyl) methacrylamide HPMA polymermedicine conjugate are combined for use, so that the capability of causing anti-tumor immune response is improved, and the anti-tumor effect is enhanced.

Description

technical field [0001] The invention relates to a combined pharmaceutical composition capable of simultaneously amplifying immunogenic cell death and enhancing anti-tumor effects and its application, in particular to cardiac glycosides and cytotoxic N-(2-hydroxypropyl)methyl The combined drug of acrylamide HPMA polymer drug conjugate and its application belong to the technical field of medicine. Background technique [0002] The incidence of cancer is increasing day by day. According to the report of the World Health Organization, there will be nearly 25 million new cancer cases in the next two decades. Cancer has gradually become an important cause of global morbidity and death, seriously endangering human health. Although people today have more and more various treatment methods for cancer and more and more drugs to choose from, most cancers are still incurable and the survival period of patients is still short. Therefore, any effective and reliable cancer treatment me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K47/58A61K33/243A61K31/555A61K31/704A61K31/7048A61P35/00
CPCA61K31/555A61K31/704A61K31/7048A61K45/06A61K47/58A61P35/00A61K33/243A61K2300/00
Inventor 黄园向宇成李炼
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap